Search results for " Pseudomonas aeruginosa"

showing 10 items of 21 documents

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infecti…

2018

ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group.

0301 basic medicineAcinetobacter baumanniiCarbapenemAntibioticsDrug ResistanceDrug resistanceTigecyclineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; SurveyPolymyxin0302 clinical medicineSurveys and Questionnairespolycyclic compounds030212 general & internal medicineAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and QuestionnairesSurveyCarbapenemAcinetobacter baumannii; Carbapenem; Carbapenem-resistant Gram-negative bacilli; Combination therapy; Enterobacteriaceae; Polymyxin; Pseudomonas aeruginosa; Survey; Anti-Bacterial Agents; Carbapenems; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals; Humans; Microbial Sensitivity Tests; Surveys and Questionnaires; Microbiology (medical); Infectious DiseasesCross InfectionbiologyMicrobial Sensitivity TestCarbapenem-resistant Gram-negative bacilliBacterialantibiotic management carbapenem-resistant Gram-negative bacteriaGeneral MedicineHospitals3. Good healthAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPseudomonas aeruginosamedicine.drugHumanMicrobiology (medical)medicine.medical_specialtymedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsFosfomycincarbapenem-resistant Gram-negative bacteria03 medical and health sciencesHospitalEnterobacteriaceaeInternal medicineAnti-Bacterial AgentDrug Resistance BacterialGram-Negative BacteriamedicineGram-Negative Bacterial InfectionHumansCombination therapyCross-Sectional Studiebusiness.industrybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycosesCross-Sectional StudiesCarbapenemsInfectious disease (medical specialty)Carbapenem-resistant gram-negative bacilli[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieantibiotic managementbusinessGram-Negative Bacterial InfectionsRifampicin
researchProduct

Antimicrobial and Antibiofilm Activity of a Recombinant Fragment of β-Thymosin of Sea Urchin Paracentrotus lividus

2018

With the aim to obtain new antimicrobials against important pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, we focused on antimicrobial peptides (AMPs) from Echinoderms. An example of such peptides is Paracentrin 1 (SP1), a chemically synthesised peptide fragment of a sea urchin thymosin. In the present paper, we report on the biological activity of a Paracentrin 1 derivative obtained by recombination. The recombinant paracentrin RP1, in comparison to the synthetic SP1, is 22 amino acids longer and it was considerably more active against the planktonic forms of S. aureus ATCC 25923 and P. aeruginosa ATCC 15442 at concentrations of 50 &micro

0301 basic medicineSettore BIO/05 - ZoologiaPharmaceutical Science<i>Staphylococcus aureus</i>Peptide<i>Paracentrotus lividus</i>Settore BIO/19 - Microbiologia Generalemedicine.disease_causebiofilmDrug DiscoveryPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5chemistry.chemical_classificationbiologyMicrobial Sensitivity TestChemistrymolecular dynamicBiological activityRecombinant ProteinAntimicrobialRecombinant ProteinsAnti-Bacterial AgentsBiochemistrySettore CHIM/03 - Chimica Generale E InorganicaStaphylococcus aureusPeptidePseudomonas aeruginosaStaphylococcus aureuParacentrotusAntibacterial activityAMP (antimicrobial peptides)Staphylococcus aureusSea UrchinAntimicrobial peptidesMicrobial Sensitivity TestsParacentrotus lividusArticle03 medical and health sciencesAnti-Bacterial AgentmedicineAnimalsAMP (antimicrobial peptides); Paracentrotus lividus; Pseudomonas aeruginosa; Staphylococcus aureus; biofilm; molecular dynamics; thymosinAnimalBiofilmthymosinbiology.organism_classificationmolecular dynamics<i>Pseudomonas aeruginosa</i>030104 developmental biologylcsh:Biology (General)Paracentrotus lividusBiofilmsSea UrchinsParacentrotuPeptidesParacentrotus lividuMarine Drugs
researchProduct

A Difficult Case of Necrotizing Fasciitis Caused By Acinetobacter baumannii

2010

This study reports the case of a 55-year-old woman with diabetes with a necrotizing fasciitis of the right lower limb and the perineum, first admitted at the emergency department for septic shock with cardiac arrest, and later transferred to the department of surgery. Microbiological and histopathological examination confirmed the diagnosis of necrotizing fasciitis caused by Acinetobacter baumanii. A broad-spectrum antibiotic therapy was administered and later readjusted according to the results of microbiological culture. Intensive hemodynamic support was required. Wounds were dressed daily with a 3 percent boric acid solution and a silver sulfadiazine-impregnated dressing. An extensive s…

Acinetobacter baumanniiInsecticidesmedicine.medical_specialtyMicrobiological culturemedicine.medical_treatmentAcinetobacter Infections/diagnosis Acinetobacter Infections/drug therapy Acinetobacter Infections/microbiology* Acinetobacter baumannii/isolation &ampSettore MED/19 - Chirurgia PlasticaBoric AcidsmedicineHumansFasciitis NecrotizingFasciitisDebridementbiologybusiness.industrySeptic shockSoft Tissue Infectionspurification* Anti-Infective Agents Local/therapeutic use Boric Acids/therapeutic use Debridement Fasciitis Necrotizing/diagnosis Fasciitis Necrotizing/drug therapy Fasciitis Necrotizing/microbiology* Female Heart Arrest Humans Insecticides/therapeutic use Middle Aged Pseudomonas aeruginosa/isolation &ampGeneral MedicineEmergency departmentMiddle Agedbiology.organism_classificationmedicine.diseaseShock SepticSilver SulfadiazineHeart ArrestSurgeryAcinetobacter baumanniiPerineummedicine.anatomical_structureDebridementShock (circulatory)Pseudomonas aeruginosapurification Shock Septic Silver Sulfadiazine/therapeutic use Soft Tissue Infections/diagnosis Soft Tissue Infections/drug therapy Soft Tissue Infections/microbiologyAnti-Infective Agents LocalFemaleSurgerymedicine.symptombusinessAcinetobacter InfectionsThe International Journal of Lower Extremity Wounds
researchProduct

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

2013

Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with nosocomial pneumonia during 2009 to 2011. Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112) , Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n = 54). The most …

Acinetobacter baumanniiSettore MED/07 - Microbiologia E Microbiologia ClinicaPenicillanic AcidDrug resistanceIranmedicine.disease_causechemistry.chemical_compoundLevofloxacinDrug Resistance Multiple BacterialPrevalenceRespiratory Tract InfectionsPolymyxin BCross InfectionbiologyCeftriaxoneGeneral MedicineHospitalsAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPiperacillin Tazobactam Drug CombinationPseudomonas aeruginosaCeftriaxonemedicine.drugMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusMicrobial Sensitivity TestsMicrobiologyTazobactamMicrobiologyAntibiotic resistanceAcinetobacter baumanniiiVirologymedicinePneumonia BacterialHumansTehran hospitalsGram-Positive Bacterial InfectionsPiperacillindrug resistancebusiness.industryPseudomonas aeruginosanosocomial pneumoniaSputumbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationchemistrynosocomial pneumonia; drug resistance; Acinetobacter baumanniii; Pseudomonas aeruginosa; Tehran hospitalsLinezolidParasitologybusinessGram-Negative Bacterial Infections
researchProduct

[Anti-Pseudomonas aeruginosa antibodies and lung disease in cystic fibrosis]

2003

The aim of our study was to diagnose and to control three aspects of the evolution of lung disease in CF: the absence of infection, the intermittent colonization and chronic infection by Pseudomonas aeruginosa. Therefore a study of anti-pseudomonas antibodies (Ab) (anti-protease, anti-elastin and antihexo-toxin A) for diagnosis and follow-up of CF patients was considered. Moreover, we related the presence of Ab to the sputum culture, to FEV1, to patient age and to genotype. Tbe Ab were dosed in 121 patients by quantitative ELISA method. Values &lt; 1: 500 were considered negative, values&gt; 1: 500 and &lt; 1:1250 borderline, and &gt; 1:1250 positive. 16.5% of patients did not have Ab, 17% …

Cystic fibrosis Pseudomonas aeruginosa
researchProduct

A novel VIM‐type metallo‐beta‐lactamase (VIM‐14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit

2011

AbstractA Pseudomonas aeruginosa highly resistant to carbapenems was isolated in a neonatal intensive care unit in Palermo, Italy. The strain was found to carry a novel VIM‐type enzyme, classified as VIM‐14. The novel enzyme differs from VIM‐4 in a G31S mutation. VIM‐14 was harboured in a class 1 integron with a new organization. The integron carried the genes aac7, blaVIM‐14, blaOXA‐20 and aac4 in that order.

DNA BacterialMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaNeonatal intensive care unitSettore MED/17 - Malattie Infettivemetallo-b-lactamaseAntibiotic resistancemetallo-β-lactamasemedicine.medical_treatmentMolecular Sequence DataMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeIntegronbeta-LactamasesIntegronscarbapenemlaw.inventionMicrobiologyAntibiotic resistancelawDrug Resistance Multiple BacterialIntensive Care Units Neonatalpolycyclic compoundsmedicineHumansVIM-14Antibacterial agentBase SequencePseudomonas aeruginosaInfant Newbornmetallo‐β‐lactamaseAntibiotic resistance; carbapenems; metallo-b-lactamase; Pseudomonas aeruginosa; VIM-14Sequence Analysis DNAGeneral Medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationIntensive care unitInfectious DiseasesPseudomonas aeruginosaBeta-lactamasebiology.proteinbacteriacarbapenemsVIM‐14PseudomonadaceaeClinical Microbiology and Infection
researchProduct

Intervención nutricional en niños y adolescentes con fibrosis quística. Relación con la función pulmonar

2005

Cecilia.Martinez@uv.es; Francisco.Nunez@uv.es; Objetivo: Evaluar los efectos de la intervención nutricional precoz y continuada en pacientes pediátricos con fibrosis quística (FQ) y su posible implicación en la función pulmonar. Pacientes y métodos: Se incluyen el seguimiento de 19 pacientes con FQ (11 niñas, 8 niños) de 17 meses a 18 años de edad y promedio de 10 años de enfermedad. El genotipo de 16 pacientes es delta F 508 (10 homo, 6 heterocigotos). Cada 2-3 meses se les ha realizado: valoración clínica, dietética y antropométrica clasificando el estado de nutrición (EN) según Z pesto/talla, % peso para la talla, índice de masa corporal y Z talla/edad. Coincidentemente se obtuvo cultivo…

Fibrosis quísticaMalnutriciónValoración nutritionalUNESCO::CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Otras:CIENCIAS MÉDICAS ::Ciencias de la Nutrición ::Otras [UNESCO]Nutrición enteralPseudomonas aeruginosaFibrosis quística; Nutrición enteral; Malnutrición; Valoración nutritional; Pseudomonas aeruginosa; Función pulmonarFunción pulmonar
researchProduct

Healthcare-Associated Pneumonia and Multidrug Resistant Bacteria: Do We Have a Convincing Answer?

2014

Methicillin-Resistant Staphylococcus aureusMicrobiology (medical)medicine.medical_specialtyBacteriabusiness.industryMedicine (all)Drug ResistanceBacterialPneumonia Ventilator-AssociatedBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)Pneumoniamedicine.diseasePneumoniaVentilator-AssociatedMultidrug resistant bacteriaInfectious DiseasesHealthcare associatedEnterobacteriaceaeDrug Resistance BacterialPseudomonas aeruginosamedicineBacteria; Enterobacteriaceae; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Ventilator-Associated; Pseudomonas aeruginosa; Drug Resistance; Bacterial; Infectious Diseases; Microbiology (medical); Medicine (all)HumansIntensive care medicinebusiness
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct

Carga y factores de riesgo para la neumonía adquirida en la comunidad de Pseudomonas aeruginosa : un estudio multinacional de prevalencia puntual de …

2018

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeru…

Pneumonia Pseudomonas aeruginosaMaleantibiotic resistanceInternationalityCross-sectional studybacterial colonizationvery elderlyPrevalenceDrug ResistanceDrug resistancePneumònia adquirida a la comunitatPseudomonas aeruginosa community acquired pneumoniaPulmonary Disease Chronic Obstructive0302 clinical medicineTracheostomyCommunity-acquired pneumoniaRisk FactorsEpidemiology80 and overPrevalenceMedicineCommunity-Acquired Infection030212 general & internal medicineAged 80 and overCross InfectionadultarticleBacterialMiddle AgedAntibiotic coverageBronchiectasisCommunity-Acquired Infectionshospital patientpriority journalrisk factorAged; Aged 80 and over; Bronchiectasis; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance Bacterial; Female; Humans; Internationality; Logistic Models; Male; Middle Aged; Pneumonia Bacterial; Prevalence; Pseudomonas aeruginosa; Pulmonary Disease Chronic Obstructive; Risk Factors; TracheostomyPseudomonas aeruginosaInfectious diseasesFemaleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveCommunity-acquired pneumoniaLogistic ModelAdmissionSettore MED/10 - Malattie Dell'Apparato Respiratoriochronic lung diseasePulmonary Disease03 medical and health sciencesBronchiectasiInternal medicinePseudomonasDrug Resistance BacterialPneumonia BacterialHumanscontrolled studyhumanAgedCross-Sectional StudieBronchiectasisbusiness.industryRisk Factorcommunity acquired pneumoniaPneumoniamedicine.diseaselogistic regression analysismajor clinical studyantibiotic sensitivityPneumoniahospital admissionCross-Sectional StudiesLogistic Models030228 respiratory systemmicrobiological examinationbusinesschronic obstructive lung disease
researchProduct